Lava Therapeutics
Financials
Estimates*
| EUR | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenues | - | 3.9m | 5.0m | 17.6m | 6.2m | 3.2m |
| % growth | - | - | 28 % | 253 % | (65 %) | (48 %) |
| EBITDA | (9.3m) | (15.2m) | (44.4m) | (31.7m) | (35.2m) | - |
| % EBITDA margin | - | (389 %) | (887 %) | (180 %) | (573 %) | - |
| Profit | (9.7m) | (16.7m) | (45.3m) | (29.0m) | (38.2m) | - |
| % profit margin | - | (426 %) | (907 %) | (165 %) | (620 %) | - |
| R&D budget | 8.3m | 16.8m | 37.2m | 36.5m | 30.7m | - |
| R&D % of revenue | - | 428 % | 744 % | 207 % | 500 % | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €1.0m | Seed | |
€16.0m | Early VC | ||
€71.0m | Series C | ||
| N/A | $100m Valuation: $380m 88.2x EV/LTM Revenues -22.6x EV/LTM EBITDA | IPO | |
| Total Funding | €88.0m | ||
Related Content
Recent News about Lava Therapeutics
EditLAVA Therapeutics is a biotechnology company focused on developing innovative cancer therapies using gamma delta T cell engagers. The company operates in the biopharmaceutical market, targeting oncology patients with its novel platform that generates bispecific gamma delta T cell engager (bsTCE) therapeutics. These therapeutics activate a unique subset of T cells called Vgamma9 Vdelta2 T cells, which have shown potent and specific activation and killing of patient-derived tumor cells in preclinical studies. LAVA Therapeutics primarily serves healthcare providers and patients in the oncology sector. The company's business model revolves around research and development, clinical trials, and eventual commercialization of its bsTCE therapeutics. Revenue is generated through partnerships, licensing agreements, and future sales of approved therapies.
Keywords: biotechnology, cancer therapy, gamma delta T cells, bsTCE, oncology, Vgamma9 Vdelta2, therapeutics, biopharmaceutical, innovation, preclinical studies.